Mabwell Biotechnology Plans to Issue H Shares
December 19, 2024
Source: drugdu
61
December 15 Mabwell Biotechnology (688062) announced a preliminary announcement regarding its plan to issue H shares and list on the Hong Kong Stock Exchange.
The announcement stated that in order to meet the funding needs for the company's operational development, achieve sustainable growth, and enhance its level of internationalization, the company intends to issue H shares abroad and list on the main board of the Hong Kong Stock Exchange.
The company will choose an appropriate time and issuance window to complete this task within the validity period of the shareholders' meeting resolution.
As of now, the company is actively discussing relevant matters concerning the H share issuance with related intermediary institutions, but specific details have not yet been finalized.
The announcement emphasized that the review and approval process for the issuance and listing of H shares involves significant uncertainties, and investors should remain vigilant about this situation. In the first three quarters of 2024, Mabwell Biotechnology-U achieved revenue of 141 million yuan and a net profit attributable to the parent company of -694 million yuan.
https://finance.eastmoney.com/a/202412153268603542.html
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Yingtai Medical acquires Weiqiang Medical December 21, 2024
- 4 innovative medical devices approved for market launch December 21, 2024
- Once a month, potential “best-in-class” lipid-lowering drugs apply for listing December 21, 2024
- Notice! Xinma Pharmaceutical Recruitment and Procurement Involved in Bribery December 21, 2024
- New weight loss drug, the world’s first cAMP-biased GLP-1 agonist has been submitted for marketing December 21, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
